About the eMDI- For patients with asthma and COPD
H&T Presspart and Cohero Health are currently collaborating with pharmaceutical manufacturers who are leveraging the technology for pipeline development and value-added product differentiation. As a fully-functioning, market-ready device, it will enable pharmaceutical manufacturers to bring the best possible care to patients with asthma and COPD in the fastest time, and in the most cost-efficient way.
The eMDI at a glance
- First market-ready, fully-embedded, intuitive, connected metered dose inhaler (eMDI) from H&T Presspart, the world’s leading manufacturer of MDI devices, and Cohero Health, an innovative digital health company that has established leading connected health tools and technologies to empower and improve the care of respiratory patients
- Enables: improved adherence, engagement in self-care and real-time monitoring by caregivers and the healthcare community
- Seamlessly integrates with BreatheSmart from Cohero Health, the only comprehensive respiratory disease management platform that enables tracking of both controller and rescue medications, along with clinically accurate lung function measurement, in real-time Wirelessly shares data with a smart phone app or directly into a patient’s medical records
- Data capture and analytical and predictive capabilities enable real-time alerts and inform clinical decision-making
- Evolution of existing inhaler technology to make it as easy as possible for patients to adopt and use, and to minimize global scale-up costs, regulatory pathway and time to market
Unique features of the eMDI
- Fully embedded device to promote adoption and repeated use to generate unadulterated data
- Seamless integration into the BreatheSmart connected respiratory care platform from Cohero Health
- Embedded sensors to detect medication use and quality of medication administration (detection of proper inhaler actuation)
- Embedded mechanical or electronic dose counting and display Intuitive and discrete design, operation consistent with standard pMDI operation
- No disruption to medication delivery pathway, reducing regulatory hurdles and expediting time to market
- Compatibility with any valve or canister
- Battery life consistent with product shelf life – no replacement parts, no recharging or battery changes
- Modular design enabling sensing and communication capabilities to be applied to a range of MDI, DPI and other drug delivery devices
Benefits of the eMDI
Improves adherence and engages and empowers patients in their self-care
- Sensors embedded within the inhaler track the date and time of medication use as well as the quality of delivery, which is both recorded in onboard memory and shared wirelessly via Bluetooth to a smartphone app.
- App provides customized reminders and updates on medication use as well as real-time alerts. For example, it can alert patients of missed doses or issues with their medication use that indicate either poor adherence or a worsening of their condition, such as increased rescue inhaler use. Such real time reminders and alerts enable the patient and caregivers to take action to reduce risk of an attack.
The only platform that allows tracking and analysis of the effects of medication use on lung function
- Medication use data from the eMDI can be merged in real-time with lung function data from Cohero Health’s mSpirometer – a clinical grade handheld wireless spirometer that precisely measures critical lung function metrics.
- Patients can opt to share their data with caregivers and/or healthcare providers, with access via a web app on a secure, dedicated, HIPPA-compliant server.
- The technology supports EMR integration, allowing patient data to be transferred automatically and securely directly into a patient’s medical record.
- Real-time monitoring connects patients to their caregivers and healthcare professional between reviews enabling them to be alerted when a patient’s condition significantly worsens and requires prompt intervention.
- Retrospective data analytics and predictive algorithms will inform clinical decision making and enable healthcare professionals to identify higher-risk patients and deliver more precise and personally-optimized asthma and COPD care.
- Treatment plans will be based on a complete and objective picture of how the patient has been using and responding to treatment between reviews, rather than on subjective patient self-reporting and a snap-shot lung function test taken at the time of the review.
For more information please contact us at eMDI@presspart.com